A mixed but positive FDA advisory panel vote combined with the looming Oct. 24 PDUFA date cast into questions whether NPS Pharmaceuticals Inc.'s recombinant human parathyroid hormone (PTH) for hypoparathyroidism, Natpara, will be approved without delay.